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Abstract
We conducted a multicenter, retrospective cohort study of patients with Streptococcus pneumoniae
bacteremia to determine factors associated with antibiotic resistance and mortality. Risk factors were
identified using multivariate logistic regression. 1,574 patients at 34 sites were enrolled. Compared
to isolates from patients not receiving an antibiotic before the index blood culture, patients receiving
an antibiotic were less likely to harbor an antibiotic susceptible organism. Susceptibility to penicillin
decreased from 78% (95% confidence interval [CI], 75−80) to 49% (95%CI, 39−59); to cefotaxime/
ceftriaxone, from 92% (95%CI, 90−93) to 82% (95%CI, 72−89); and to macrolide, from 84% (95%
CI, 82−87) to 55% (95%CI, 41−68). Factors associated with macrolide non-susceptibility include:
>24 hours of antibiotic therapy at time of the index culture (odds ratio [OR] 4.0), residing in southern
U.S. (OR 1.7), and having an antibiotic allergy (OR 1.7). Harboring an antibiotic non-susceptible
strain (OR 1.4) and male sex (OR 1.4) were associated with increased risk of mortality, whereas
Black race (OR 0.6) and evidence of focal infection (OR 0.6) were associated with decreased risk.
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Introduction
Despite the long standing use of the 23-valent pneumococcal vaccine in specific at risk groups
over the age of two years, and the recent introduction of the conjugate pneumococcal vaccine
into the childhood immunization schedule in the United States, Streptococcus pneumoniae
remains the leading bacterial cause of community-acquired pneumonia, otitis media, and
meningitis among both adults and children. As recently as 1980, 99% of Streptococcus
pneumoniae were fully susceptible to penicillin, and thus treatment of community-acquired
pneumonia with a beta-lactam antibiotic was justified. Due to concerns about increasing
pneumococcal resistance to penicillin, and to provide coverage for atypical pathogens, the
American Thoracic Society and Infectious Disease Society of America now recommend
considering the use of a macrolide antibiotic plus high dose beta-lactam antibiotic for the
empiric outpatient treatment of community acquired pneumonia.(1-4) Recent surveillance
studies of invasive pneumococcal isolates have demonstrated that only 73% of isolates remain
susceptible to penicillin, and 78% susceptible to erythromycin. (5)
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The use of low dosages and long treatment duration with beta-lactam antibiotics have been
identified as risk factors for the nasopharyngeal carriage of penicillin resistant organisms. (6)
Underlying disease, immunosupression and prior antibiotic use have also been associated with
penicillin non-susceptibility in prior studies.(7,8) Despite the recognized increased rates of
antimicrobial resistance among pneumococci, the clinical significance of this resistance is
largely unknown. There is literature suggesting that antibiotic resistance may contribute to
treatment failure and poor clinical outcomes.(7,9-11) Cases of failed therapy in association
with resistance have been reported, but large-scale clinical studies of this phenomenon are
lacking. The result is poor consensus regarding the clinical implications of antimicrobial
resistance. For example, some authors contend that beta-lactam resistance as currently defined
should only impact on the therapy of meningitis, or that macrolide resistance as currently
defined does not correlate with clinical failure. Some recent reports, however, are worrisome
with reported development of pneumococcal bacteremia among patients receiving
azithromycin or clarithromycin therapy, in association with low-level resistant strains.
(12-15)
We performed this large multicenter U.S. study including over 1500 patients with
pneumococcal bacteremia in order to increase our understanding regarding factors associated
with antibiotic resistance and associated mortality. We will describe the susceptibility pattern
of pneumococcal isolates in this cohort, and will determine the factors associated with antibiotic
resistance and mortality.
Materials and Methods
We performed a multicenter, retrospective case-control study of patients with Streptococcus
pneumoniae bacteremia. Investigators at 34 U.S. sites reviewed the medical records of these
subjects using a standardized protocol. All sites are members of the Emergency Medicine
Network (EMNet), a clinical research collaboration with greater than 140 participating medical
centers.(6) Site selection for participation was based on the local microbiology lab routinely
performing pneumococcal susceptibility testing and with consideration of their geographic
location. The study was approved by the institutional review board at each of the 34
participating hospitals.
Each site was asked to produce a list of all patients with pneumococcal bacteremia over at least
one year since January 1, 2000. If less than 50 patients were listed in 2000, sites were asked
to continue collecting patients into 2001 and 2002 until reaching 50 subjects. Patient lists were
produced by the hospital's microbiology laboratory, which identified eligible subjects as those
with growth of S. pneumoniae in blood culture. Sites submitted completed patient lists to the
EMNet Coordinating Center, where lists were checked for repeat patients and assigned
randomized numbers. Data was collected for only one visit per patient, such that only the first
visit for that patient was included in the analysis, and subsequent visits by that patient for the
same or subsequent episodes of bacteremia were excluded. The patient lists were sorted by
assigned randomization number and site and the principal investigator at each site completed
a data abstraction form for the first 50 patients from their randomly sorted list. If one of the 50
charts was a lost medical record, the next chart on the list was used. Sites that did not accrue
50 patients during the study period collected data on each of the eligible patients seen at the
site during the study period.
Data collection was done using a standardized protocol and data abstraction form. For all charts,
basic demographic information, diagnosis, the presence of a focal site of infection, and key
clinical information was obtained. Documentation was obtained regarding hospitalization and
prior antimicrobial therapy within the month prior to developing bacteremia. Investigators also
recorded whether the blood culture was obtained in the office/clinic, ED, or as an inpatient and
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whether or not the patient was admitted for the illness. The final disposition of admitted patients
was also recorded.
The result of laboratory susceptibility testing of the S. pneumoniae isolates and specific
methodology was recorded. All forms were reviewed by site investigators before submission
to the EMNet Coordinating Center in Boston, where they underwent further review by trained
personnel and then double data entry. Determination of prior antibiotic therapy was based on
the response to the following question: Is there evidence of > 24 hours of antibiotic therapy
before the time the blood culture was drawn? Available selections were: yes, no or unsure. We
considered a patient to have therapeutic failure if the answer to the above question was yes,
i.e. bacteria was identified from a culture of blood obtained from the patient after more than
twenty-four hours of antibiotic treatment.
S. pneumoniae is reported as susceptible, intermediate, or resistant to the tested antibiotic.
Twenty-nine of the sites used NCCLS criteria to define these categories; five sites used alternate
but nearly identical criteria (similar Minimal Inhibitory Concentration (MIC) and Zone
Diameter breakpoints as those defined by NCCLS criteria to delineate each category. For the
purposes of these analyses, both intermediate and resistant organisms will be considered as
non-susceptible strains. Antibiotic susceptibility testing listed on the data form included:
penicillin, cefotaxime / ceftriaxone, erythromycin, clindamycin, tetracycline, and
trimethoprim / sulfamethoxazole.
All analyses were performed using STATA 7.0 (StataCorp, College Station, TX). Data are
presented as proportions (with 95% confidence intervals [CI]), means (with standard deviation
[SD]), or medians (with interquartile range [IQR]). The association between antibiotic
susceptibility and other factors was examined using Chi-square test, Student's t-test, and
Wilcoxon rank sum test, as appropriate. Age, sex, and race were included in the multivariate
models because of their potential clinical significance. Other variables associated with
resistance at p<0.10 in univariate analysis were evaluated for inclusion in multivariate logistic
regression. The final models were further evaluated using the Hosmer-Lemeshow test. All p-
values are two-sided, with p<0.05 considered statistically significant.
Results
A total of 1,574 patients at 34 sites were included in the study. 99 patients (6%:95% CI 5, 8)
had received >24 hours of antibiotic therapy before the time that the blood was drawn for
culture; of whom 38% had received a macrolide antibiotic, 31% a sulfonamide, 16% a
cephalosporin, 16% a quinolone, and 7% of study subjects received a penicillin. 1423 patients
had not received an antibiotic prior to the collection of a blood culture, and we were unable to
determine prior antibiotic status in 52 patients.
Demographic characteristics of these patients with pneumococcal bacteremia are shown in
Table 1. There is a bimodal distribution for age, which peaks at 1−5 years and 40−49 years of
age. The median age was 46 years, with a similar number of men and women. Consistent with
the urban setting of the study hospitals, half of the subjects were black or Hispanic. Subjects
came from all regions of Unites States, with preponderance from Northeast (consistent with
location of most EMNet sites). Patients were covered by a diverse array of third-party payers.
Clinical characteristics of patients with pneumococcal bacteremia are shown in Table 2. Forty-
four percent of patients with prior antibiotic therapy were immunocompromised, compared to
23% of those not receiving antibiotics at the time of blood collection. Human
Immunodeficiency Virus infection accounted for 56% of immunocompromise overall, and
29% were chemotherapy related. A primary site of infection was documented for 78% of
patients, with pneumonia being most common (63% of all patients, and 82% of those with a
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documented site of infection). Twenty-two percent of patients had no focal site of infection
identified. The majority of subjects (74%) had blood drawn for culture within an emergency
department. For those with blood drawn within the ED or clinic (total of 79%), 88% were
admitted to the hospital. Thirteen percent of hospitalized patients with S. pneumoniae
bacteremia died.
Antibiotic susceptibilities of S. pneumoniae isolates are detailed in Table 3. Testing varied
widely across sites, with most hospitals testing for penicillin (99%) and cephalosporins (85%).
Fewer tested for susceptibility to macrolides (62%) and quinolones (47%). Patients already
receiving an antibiotic at the time they developed bacteremia were more likely than patients
not currently receiving antibiotics, to harbor an antibiotic non-susceptible organism. For
example, penicillin susceptibility decreased from 78% to 49%, and macrolide susceptibility
decreased from 84% to 55%. Among patients taking a penicillin (n=7) at the time they
developed pneumococcal bacteremia, 43% had a penicillin susceptible isolate. Similarly, 20%
of patients receiving a cephalosporin (n=15), and 60% of those receiving a macrolide (n=38)
antibiotic had a pneumococcal isolate which was susceptible to the antibiotic they were
receiving.
Of the 344 pediatric patients under 18 years of age, 28 (8.1%) had received antibiotic therapy
prior to obtaining blood for culture. A similar reduction in proportion of antibiotic susceptible
strains was observed in this group. Pneumococcal isolates from children receiving a macrolide
prior to blood culture collection were more likely to be a macrolide non-susceptible organism
(33% susceptible vs. 81% susceptible). Additionally, among children taking a non-macrolide
antibiotic (penicillin, cephalosporin, etc.), the proportion with isolates susceptible to penicillins
(75% vs. 59% susceptible), cephalosporins (91% vs. 86%), as well as macrolides (81% vs.
73%) were decreased. Similar reductions in the proportion of susceptible isolates were
observed among elderly patients (≥65 years of age).
Univariate predictors of macrolide resistance include: residence in Southern US (as defined by
U.S. Census Bureau Estimates), prior antibiotic therapy, and immunocompromise (data not
shown). Multivariate models for macrolide, penicillin, and cephalosporin non-susceptibility
are shown in Table 4. Adjusting for covariates, predictors that confer increased risk of
macrolide resistance include: evidence of prior antibiotic therapy (OR = 4.0), residing in the
Southern United States (OR = 1.7), and having an allergy to an antibiotic (OR = 1.7). Predictors
for penicillin and cephalosporin non-susceptibility were similar; prior antibiotic therapy
remained significant in the penicillin and cephalosporin models with OR's = 3.3 and 2.0
respectively. Admission to the hospital within the preceding month was a risk factor for both
penicillin (OR = 1.5) and cephalosporin (OR = 2.6) non-susceptibility, whereas having an
allergy to an antibiotic did not reach statistical significance in these two models. Increasing
age was not a risk factor for macrolide, penicillin or cephalosporin non-susceptibility.
Exclusion of children (n=344) did not materially change the results (data not shown).
Thirteen percent of patients with pneumococcal bacteremia died. A multivariate model of
mortality among patients with pneumococcal bacteremia is shown in Table 5. Antibiotic
nonsusceptibility (macrolide or penicillin or cephalosporin) was found to be a significant
predictor of mortality among patients with pneumococcal bacteremia (OR = 1.4). Univariate
analysis of antibiotic non-susceptibility on mortality are as follows: macrolide non-
susceptibility (OR=1.2, 95% CI 0.9, 1.8), penicillin non-susceptibility (OR=1.2, 95% CI 1.0,
1.5), and ceftriaxone or cefotaxime non-susceptibility (OR=1.3, 95% CI 0.9, 1.5). Male patients
(OR =1.4), as well as patients that were either admitted to the hospital or were an inpatient at
the time the blood culture was drawn (OR = 5.1) had an increased risk of mortality compared
with those not admitted to the hospital. Increasing age was also associated with risk of mortality
(OR = 1.3). Current antibiotic use was not associated with increased risk of mortality. The
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presence of a reported focal infection conferred a decreased risk of mortality (OR 0.6).
Additionally, Blacks had a lower risk of mortality (OR = 0.6) compared to whites. Limiting
the analysis to adults did not alter our results (data not shown).
Discussion
Streptococcus pneumoniae remains the leading cause of invasive bacterial diseases such as
community-acquired pneumonia and meningitis in the United States. (5,16-19) Despite
widespread reports of decreased susceptibility of S. pneumoniae to penicillins, cephelosporins,
and macrolides, these remain the most commonly prescribed antibiotics for both children and
adults with community acquired pneumonia in the United States and Canada. (4,12) With
increasing rates of antibiotic resistance of S. pneumoniae, decisions on treatment of patients
with such infections may depend on local antimicrobial susceptibility, as well as clinical
outcomes of patients treated with these antibiotics. Prior studies investigating the clinical
relevance of antibiotic resistance and mortality in pneumococcal disease have been based on
a much smaller number of patients.(11,12)
In this large, retrospective mulitcenter cohort study of patients with pneumococcal bacteremia,
we determine the relationship between prior antibiotic use and antibiotic resistance, and also
determine which factors are associated with antibiotic resistance. We found that in addition to
prior antibiotic use, having S. pneumoniae isolated from another site in addition to blood,
residing the Southern US, and having an allergy to an antibiotic are independent risk factors
for harboring a macrolide resistant organism.
Six percent of patients with identified pneumococcal bacteremia were already receiving an
antibiotic as treatment for an infection at the time blood was drawn for culture. If the
pneumococcus in these patients were fully susceptible to the antibiotic used, we suspect that
these patients would have cleared the bacteremia, or when secondary to other focal infections,
not have developed bacteremia.(20,21) Thus we consider these patients to have failed
antimicrobial therapy. Among these patients, we observed a significantly higher rate of
antimicrobial resistance, not only for the antibiotic they were currently receiving, but for other
tested antibiotics as well. Thus, if a patient develops pneumococcal bacteremia while taking
an antibiotic, the clinician should consider changing the antibiotic selected, or changing the
dose or the route of therapy- taking into consideration the likelihood that the isolate will have
reduced susceptibility or be non-susceptible to the current and other antibiotics. Due to the
case-control design of this study, and the analysis of only patients that developed pneumococcal
bacteremia, these results should not be extrapolated to all patients at risk of pneumococcal
disease, particularly those with community-acquired pneumonia.
In our study, macrolides were the most common prior antibiotic used among patients that
developed pneumococcal bacteremia, followed closely by sulfonamides. Penicillins and
cephalosporins were used less frequently. Perhaps this is due to the fact that the use of beta-
lactam antibiotics has been limited by the increasing prevalence of pneumococcal resistance
to these agents. It should be noted that most of the decrease in cephalosporin and penicillin
susceptibility attributed to prior antibiotic use appears to be due to an increase in intermediate
resistant strains. Nearly all isolates, even among patients that had received prior antibiotic
therapy, remained susceptible to quinolones.
Since the emergence of resistance of S. pneumoniae to beta-lactams such as penicillins, and to
provide coverage against atypical pathogens, macrolides have become a mainstay of therapy
for adults with pneumonia. Their use however has been questioned due to the rising rate of
resistance of S. pneumoniae to macrolides over the past decade. Two types of macrolide
resistance patterns have been identified among pneumococcal strains. “High level resistance”
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is associated with the MLSB phenotype, and the presence of the erm gene, which codes for
ribosomal methylase. “Low/ intermediate level resistance” (M phenotype), is associated with
presence of the mef gene, which codes for a macrolide efflux pump. Most macrolide resistance
within the United States has been of the low level type; these pneumococci remain susceptible
to clindamycin.(22) There are conflicting data on whether this type of resistance correlates
with clinical failure among patients with invasive pneumococcal disease treated with macrolide
antibiotics.(7,9,10,13,17,23,24)
The strongest predictor of macrolide resistance among patients with pneumococcal bacteremia
was prior antibiotic use. Patients who have received > 24 hours of antibiotics therapy at the
time the blood culture was drawn were four times more likely to harbor a macrolide resistant
organism, compared to those not receiving prior antibiotic therapy. Prior antibiotic therapy was
also a significant risk factor for harboring a penicillin and cephalosporin resistant organism.
This is consistent with the results of numerous other studies, (7,8,12,25,26) and is not
surprising, considering that the selective pressure exerted on organisms by antibiotics, forces
species to develop mechanisms of resistance to allow for its survival. These results should be
framed in the context that it is likely that the patients included in this study had organisms
which were already resistant to the antibiotic prescribed. It is also not surprising that the most
common antibiotics we observed used among patients that developed pneumococcal
bacteremia were macrolides, as the current guidelines for treatment of community-acquired
pneumonia recommend the use of a macrolide for outpatient treatment. Since this is a case-
control study, we are essentially only including patients that did not successfully treat their
infections, and thus, we are unable to draw any conclusions about the effectiveness of
macrolides overall.
In our multivariate model, we found that residence in the Southern U.S. confers an increased
risk of harboring a macrolide and penicillin resistant pneumococcal organism. This is
consistent with the findings from the PROTEKT US (Prospective Resistant Organism Tracking
and Epidemiology for the Ketolide Telithromycin in the United States) surveillance program
conducted in 2000 / 2001, which found a high rate of penicillin and macrolide resistance among
respiratory tract pathogens in the Southern U.S..(27) Higher rates of antibiotic resistance in
general has been documented in the Southern U.S., where up to 38% of Streptococcus
pneumoniae species are reported to be non-susceptible to penicillin, compared to
approximately 25% nationwide.(17,25)
It is not entirely understood why patients with allergies to antibiotics would be more likely to
harbor macrolide resistant organism. The presence or knowledge of an antibiotic allergy may
serve as a proxy for prior or frequent antibiotic use. Hospitalization within the preceding month
is also associated with harboring a penicillin and cephalosporin non-susceptible organism. This
may be due to antibiotic therapy during hospitalization, to associated co-morbid conditions
and / or immunosupression, or exposure to virulent strains.
Antibiotic non-susceptibility, male sex, increasing age, and admission to the hospital were
associated with increased odds of mortality among patients with pneumococcal bacteremia.
There is much debate over whether antibiotic resistance, and macrolide resistance in particular,
contributes to clinical failure among individuals with invasive pneumococcal disease. We
found that after adjusting for other factors, harboring an antibiotic non-susceptible organism
conferred 40% higher odds of mortality. We did not collect detailed information regarding
severity of illness, co-morbidities, hospital course (including antibiotics given), and thus the
only predictors of mortality that we are able to comment on are those available at the time the
patient developed bacteremia. These unmeasured factors are likely to affect mortality, and will
require further study.
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Although antibiotic therapy at the time the blood culture was obtained was found to be a risk
factor for antibiotic resistance, it did not contribute to overall mortality. As noted above, there
are many factors relating to hospital course that were not obtained as part of this study, and
which may affect these results. Black race, and the presence of a focal infection, such as
pneumonia, were associated with a decreased risk of mortality among patients with
pneumococcal bacteremia. To our knowledge, this is the first study documenting a decreased
risk of mortality among Blacks with pneumococcal bacteremia; the reason for this is not clear.
Additionally, we would have predicted that patients without a focus of infection would have
a better outcome, as a majority of children with Streptococcus pneumoniae bacteremia without
an identified focus generally have an excellent outcome. Perhaps patients with a focus of
infection are presenting for medical care earlier than patients without a focus of infection, who
may be more critically ill upon arrival to the health care system.
Although this study involved 34 sites, it is possible that these sites were not representative of
patients with pneumococcal bacteremia within the U.S., and may not be generalizable to all
patients with pneumococcal bacteremia. Additionally, the type of macrolide resistance
predominately seen in the U.S. (M phenotype) differs from that seen in Europe and other parts
of the world (MLSB phenotype). Thus outcomes of patients with pneumococcal bacteremia
treated with macrolide antibiotics are likely to be different between the two populations. Due
to our small number of pediatric patients (seven deaths), we are unable to assess risk factors
for mortality in this age group.
One limitation of our case-control design is that the study population may not be representative
of all patients that were prescribed antibiotics for presumed or possible pneumococcal
infections. Macrolides were the most common antibiotic used among patients who developed
pneumococcal bacteremia in our study, however they may not have been the most common
antibiotic prescribed for infections that subsequently resulted in pneumococcal bacteremia. For
example, patients that received penicillins or cephalosporins for their initial infection may have
clinically improved and would not have developed pneumococcal bacteremia, and thus, would
not be included in our study.
In summary, among patients with pneumococcal bacteremia we have identified the following
risk factors for harboring a S. pneumoniae macrolide non-susceptible strain: residence in
southern U.S., evidence of prior antibiotic therapy, and presence of an antibiotic allergy. We
have also demonstrated that antibiotic non-susceptibility and male sex are risk factors for
mortality among patients with pneumococcal bacteremia. Taken together, these observations
increase our understanding of antibiotic resistance among patients with pneumococcal
bacteremia, and provide a strong foundation for future prospective studies of therapy for
pneumococcal infections.
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Table 1
Demographic Characteristics of Patients with Pneumococcal Bacteremia.
  Prior antibiotic therapy NO prior antibiotic
n=99 % (95%CI) n=1423 % (95%CI)
Age, years (median [IQR]) 99 40 (33 − 48) 1423 47 (45 − 48)
Male sex 57 58 (47 − 67) 763 54 (51 − 56)
Race
 White 48 48 (38 − 59) 650 46 (43 − 48)
 Black 28 28 (20 − 38) 535 38 (35 − 40)
 Hispanic 18 18 (11 − 27) 171 12 (10 − 14)
 Other* 5 5 (2 − 11) 67 5 (4 − 6)
Region
 Northeast 34 34 (25 − 45) 630 44 (42 − 47)
 Midwest 19 19 (12 − 28) 359 25 (23 − 28)
 South 19 19 (12 − 28) 243 17 (15 − 19)
 West 27 27 (19 − 37) 191 13 (12 − 15)
Insurance Type
 Commercial/private HMO 36 36 (27 − 47) 483 34(31 − 36)
 Medicaid 32 32 (23 − 42) 366 26(23 − 28)
 Other public 19 19 (12 − 28) 318 22(21 − 25)
 None 11 11 (6 − 19) 194 14 (12 − 16)
 Missing/unknown 1 1 (0.03 − 5) 62 4(3 − 6)
*
includes other race, Asian, missing, and, unknown
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Table 2
Clinical Characteristics of Patients with Pneumococcal Bacteremia.




Admitted within past 30 days 16 16 (10 − 25) 122 9 (7 − 10)
Immunocompromised 44 44 (34 − 55) 322 23 (20 − 25)
Antibiotic allergy 27 27 (19 − 37) 224 16 (14 − 18)
Focal Infection 77 78 (68 − 86) 1101 77 (75 − 80)
 Site of infection *
  Pneumonia 62 63 (53 − 72) 910 64 (61 − 66)
  Meningitis 10 10 (4 − 16) 39 3 (2 − 4)
  Septic arthritis 1 1 (0 − 3) 15 1 (1 − 2)
  Skin 0 0 (0 − 1) 10 1 (0 − 1)
  Multiple sites 2 2 (0 − 7) 30 2 (1 − 3)
  Otitis media, endocarditis,
catheter, other
13 13 (6 − 20) 94 7 (5 − 8)
  Missing 1 1 (0 − 5) 5 <1 (0 − 1)
If blood drawn in ED or Clinic:
ED/Clinic disposition
N=78 N=1131
 Admit/observation 44 56 (45 − 68) 663 59 (56 − 62)
 Admit ICU 26 33 (23 − 45) 259 23 (20 − 25)
 Sent home/outpatient only 7 9 (4 − 18) 193 17 (15 − 19)
 AMA / other 1 1 (.03 − 7) 16 1 (.8 − 2)
Final hospital disposition
 Sent home 70 71 (61 − 79) 1053 74 (72 −76)
 Long term / rehab 8 8 (4 − 15) 143 10 (9 − 12)
 Deceased 14 14 (8 − 23) 188 13 (11 − 15)
 Other/missing 7 7 (3 − 14) 39 3 (2 − 4)
*
not mutually exclusive
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Table 4





Model for Penicillin Non-




Age (per 10 years ↑) 1.0 (0.92, 1.07) 1.0 (0.92, 1.03) 1.0 (0.90, 1.06)
Male 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 1.1 (0.7, 1.6)
White 1.3 (0.9, 1.9) 1.2 (0.9, 1.5) 1.0 (0.6,1.5)
Region
 Northeast Reference Reference Reference
 Midwest 0.9 (0.6, 1.5) 0.8 (0.6, 1.2) 0.8 (0.5, 1.4)
 South 1.7 (1.1, 2.8)* 1.9 (1.4, 2.7) * 1.6 (0.9, 2.6)
 West 1.2 (0.6, 2.2) 0.9 (0.6, 1.3) 0.3 (0.1, 0.7) *
Medicaid insurance 1.0 (0.7, 1.6) 1.0 (0.7, 1.3) 0.6 (0.3, 0.96) *
Evidence of prior antibiotic drug therapy 4.0 (2.1, 7.3)* 3.3 (2.1, 5.1) * 2.0 (1.04, 3.8) *
Immunosuppressed patient 1.5 (1.0, 2.2) 1.5 (1.1, 2.0) * 1.3 (0.8, 2.1)
Admitted over night in past month 1.5 (0.9, 2.5) 1.5 (1.01, 2.3)* 2.6 (1.5, 4.5) *
Focal infection 0.9 (0.6, 1.4) 0.9 (0.7,1.3) 0.7 (0.4, 1.1)
Antibiotic allergy 1.7 (1.1, 2.6)* 1.3 (0.9, 1.8) 1.4 (0.9, 2.3)
Macrolide Model
Of n=893 in model, n=159 had intermediate/resistant test results.
Area under the ROC curve: 0.67, Hosmer-Lemeshow goodness of fit p-value: 0.56
Penicillin Model
Of n=1412 in model, n=350 with intermediate/resistant test results.
Area under the ROC curve: 0.65, Hosmer-Lemeshow p-value: 0.57
Cephalosporin Model
Of n=1210 in model, n=111 with intermediate/resistant test results.
Area under the ROC curve: 0.69, Hosmer-Lemeshow p-value: 0.49
*
Confidence intervals that do not cross 1 are statistically significant
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Table 5
Multivariate model of mortality
Odds Ratio 95% CI
Any antibiotic non-susceptible strain (including macrolide,
penicillin, cephalosporin)
1.4* 1.01 2.1
Evidence of prior antibiotic drug therapy 1.0 0.5 1.9
Inpatient or admitted from ED § 5.1* 2.0 13.0
Age (per 10 year increase) 1.3* 1.2 1.4
Male 1.4* 1.02 2.0
Race
 White 1.0 Reference
 Black 0.6* 0.4 0.9
 Hispanic 1.3 0.7 2.2
 Other 0.8 0.3 2.0
Region
 Northeast 1.0 Reference
 Midwest 1.2 0.8 1.7
 South 0.7 0.4 1.2
 West 1.0 0.6 1.6
Insurance status
 Private/commercial 1.0 Reference
 Medicaid 0.9 0.5 1.4
 Other public 1.0 0.7 1.5
 None 1.3 0.8 2.2
Admitted overnight in past month 1.6 0.99 2.6
Immunosuppressed 1.2 0.98 1.5
Focal infection 0.6* 0.4 0.9
Allergy to antibiotics 1.0 0.7 1.4
Of n=1433 in model, there were 189 deaths
Area under ROC 0.73, Hosmer-Lemeshow p-value =0.42
*
Confidence intervals that do not cross 1 are statistically significant
§
Definition of "Inpatient or admitted from ED": If blood culture location is inpatient OR if blood culture location is ED and disposition=admitted OR if
blood culture location is clinic and disposition=admitted
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